Advertisement

European Journal of Epidemiology

, Volume 34, Issue 3, pp 221–222 | Cite as

Theory meets practice: a commentary on VanderWeele’s ‘principles of confounder selection’

  • Sebastian SchneeweissEmail author
COMMENTARY

When I teach graduate students in pharmacoepidemiology they are well-trained by having taken multiple courses in epidemiologic methods and causal inference. I observe that many feel paralyzed when confronted with real data realizing that such data do not come with tags saying whether variables are common causes of the exposure and outcome or whether they are instrumental variables or colliders. How will they connect the concepts, rules, and exemptions they have learned studying causal inference to the reality of data? Tyler VanderWeele is to be applauded for having compassion with us who spend less time contemplating DAGs and still want to do non-experimental studies that lend themselves to causal conclusions. His pragmatic recommendations are actionable for a broad range of applications yet founded in principled considerations. I tried to put them to a test.

I am a pharmacoepidemiologist and study the safety and effectiveness of medications as they are used in routine care without the...

Notes

Funding

This work was funded partially by the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, the FDA (HHSF223201710186C) and PCORI. This article reflects the views of the author and should not be construed to represent FDA’s views or policies.

Compliance with ethical standards

Conflict of interests

Dr. Schneeweiss is a consultant to WHISCON, LLC and to Aetion, Inc. of which he also owns equity. He is the principal investigator of Grants to the Brigham and Women’s Hospital from Bayer, Vertex, and Boehringer Ingelheim unrelated to the topic of this paper.

References

  1. 1.
    Patorno E, Garry EM, Patrick AR, et al. Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Drug Saf. 2015;38:295–310.CrossRefGoogle Scholar
  2. 2.
    Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858–68.CrossRefGoogle Scholar
  3. 3.
    Zhou M, Wang SV, Leonard CE, et al. Sentinel modular program for propensity score-matched cohort analyses: application to glyburide, glipizide, and serious hypoglycemia. Epidemiology. 2017;28:838–46.CrossRefGoogle Scholar
  4. 4.
    Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–37.CrossRefGoogle Scholar
  5. 5.
    Glynn RJ, Monane M, Gurwitz JH, Choodnovskiy I, Avorn J. Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Am J Epidemiol. 1999;149:541–9.CrossRefGoogle Scholar
  6. 6.
    Schneeweiss S. Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. Clin Epidemiol. 2018;10:771–88.CrossRefGoogle Scholar
  7. 7.
    Ju C, Wyss R, Franklin JM, Schneeweiss S, Haggstrom J, van der Laan MJ. Collaborative-controlled LASSO for constructing propensity score-based estimators in high-dimensional data. Stat Methods Med Res. 2017.  https://doi.org/10.1177/0962280217744588.Google Scholar
  8. 8.
    Wyss R, Schneeweiss S, van der Laan M, Lendle SD, Ju C, Franklin JM. Using super learner prediction modeling to improve high-dimensional propensity score estimation. Epidemiology. 2018;29:96–106.CrossRefGoogle Scholar
  9. 9.
    Bross ID. Spurious effects from an extraneous variable. J Chronic Dis. 1966;19:637–47.CrossRefGoogle Scholar
  10. 10.
    Schneeweiss S, Eddings W, Glynn RJ, Patorno E, Rassen J, Franklin JM. Variable selection for confounding adjustment in high-dimensional covariate spaces when analyzing healthcare databases. Epidemiology. 2017;28:237–48.CrossRefGoogle Scholar
  11. 11.
    Myers JA, Rassen JA, Gagne JJ, et al. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011;174:1213–22.CrossRefGoogle Scholar
  12. 12.
    Liu W, Brookhart MA, Schneeweiss S, Mi X, Setoguchi S. Implications of M bias in epidemiologic studies: a simulation study. Am J Epidemiol. 2012;176:938–48.CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Division of Pharmacoepidemiology and Pharmacoeconomics, Department of MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations